prostatic neoplasms

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
Pengfei Xu, Joy C Yang, Bo Chen, Christopher Nip, Jonathan E Van Dyke, Xiong Zhang, Hong-Wu Chen, Christopher P Evans, William J Murphy, Chengfei Liu

Journal for ImmunoTherapy of Cancer May 2023, 11 (5) e006581; DOI: 10.1136/jitc-2022-006581
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report
Darien E Reed-Perino, Michael Lai, Evan Y Yu, Michael T Schweizer

Journal for ImmunoTherapy of Cancer May 2023, 11 (5) e006794; DOI: 10.1136/jitc-2023-006794
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes
Anna Sofia Trigos, Anupama Pasam, Patricia Banks, Roslyn Wallace, Christina Guo, Simon Keam, Heather Thorne, kConFab, Catherine Mitchell, Stephen Lade, David Clouston, Alexander Hakansson, Yang Liu, Benjamin Blyth, Declan Murphy, Nathan Lawrentschuk, Damien Bolton, Daniel Moon, Phil Darcy, Ygal Haupt, Scott G Williams, Elena Castro, David Olmos, David Goode, Paul Neeson, Shahneen Sandhu

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e003744; DOI: 10.1136/jitc-2021-003744
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer
Douglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, Christos E Kyriakopoulos, Ellen Wargowski, Tommaso P Tonelli, Laura E Johnson, Glenn Liu

Journal for ImmunoTherapy of Cancer Dec 2023, 11 (12) e008067; DOI: 10.1136/jitc-2023-008067
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy
Analena Handke, Claudia Kesch, Wolfgang Peter Fendler, Tugce Telli, Yang Liu, Alexander Hakansson, Elai Davicioni, Jason Hughes, Hong Song, Katharina Lueckerath, Ken Herrmann, Boris Hadaschik, Robert Seifert

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007354; DOI: 10.1136/jitc-2023-007354
YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6
Saisai Chen, Kai Lu, Yue Hou, Zonghao You, Chuanjun Shu, Xiaoying Wei, Tiange Wu, Naipeng Shi, Guangyuan Zhang, Jianping Wu, Shuqiu Chen, Lihua Zhang, Wenchao Li, Dingxiao Zhang, Shenghong Ju, Ming Chen, Bin Xu

Journal for ImmunoTherapy of Cancer Apr 2023, 11 (4) e006020; DOI: 10.1136/jitc-2022-006020
Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells
Sheng Wang, Maohua Huang, Minfeng Chen, Zhiting Sun, Yubo Jiao, Geni Ye, Jinghua Pan, Wencai Ye, Jianfu Zhao, Dongmei Zhang

Journal for ImmunoTherapy of Cancer Jun 2023, 11 (6) e006381; DOI: 10.1136/jitc-2022-006381
Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
Madeline Dahut, Kristen Fousek, Lucas A Horn, Shantel Angstadt, Haiyan Qin, Duane H Hamilton, Jeffrey Schlom, Claudia Palena

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007386; DOI: 10.1136/jitc-2023-007386
BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer
Chi Yin, Min Wang, Yingzhao Wang, Qijun Lin, Kaiyuan Lin, Hong Du, Chuandong Lang, Yuhu Dai, Xinsheng Peng

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e005532; DOI: 10.1136/jitc-2022-005532
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
Karen A Autio, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Tian Zhang, Xin-Hua Zhu, Hani Babiker, Nicholas J Vogelzang, Sandip M Prasad, Michael T Schweizer, Ravi A Madan, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Ray Li, Kam Chan, Helen Cho, Megan Kaneda, I-Ming Wang, Jenny Zheng, Szu-Yu Tang, Robert Hollingsworth, Kenneth A Kern, Daniel P Petrylak

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e005702; DOI: 10.1136/jitc-2022-005702

Main menu

prostatic neoplasms

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

prostatic neoplasms

Pages